Ironwood Pharma (IRWD) Tops Q4 EPS by 6c, Revenues Beat; Offers FY20 Revenue Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Ironwood Pharma (IRWD) Tops Q4 EPS by 6c, Revenues Beat; Offers FY20 Revenue Guidance Below Consensus

Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance

February 13, 2020 7:00 AM EST

2019 revenue of $428 million, driven primarily by U.S. LINZESS® (linaclotide) collaboration revenue

GAAP net income from continuing operations of $59 million and adjusted EBITDA from continuing operations of $148 million for the full year 2019

2020 total revenue and adjusted EBITDA guidance incorporates previously amended agreements with Astellas and AstraZeneca

Data readouts from MD-7246 Phase II trial and IW-3718 Phase III trials expected in 2020

BOSTON--(BUSINESS... More